Cashu
Revance Therapeutics Gains FDA Approval for RHA® Dynamic Volume in Aesthetic Treatments
3 months ago
Stocks
Health Care
rvnc
Revance Therapeutics
NASDAQ: RVNC
0.00 (0.00%)
3.65
USD
At close at Apr 01, 17:08 UTC
Overview
Loading chart...
Key Stats
Market Cap
382.61M
Dividend Yield
0.00%
P/E Ratio
-2.07
EPS
-1.68
Revenue
237.08M
Avg. Volume
-
About
What does RVNC do?
Revance Therapeutics, a clinical stage biotechnology company based in Nashville, develops novel botulinum toxin products, including DAXXIFY and the RHA Collection of dermal fillers. The company partners with Viatris and Fosun for biosimilar development and commercialization in China.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.